awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q41386664-4F58DD0F-017F-4376-8A53-7D473123D6C5
Q41386664-4F58DD0F-017F-4376-8A53-7D473123D6C5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41386664-4F58DD0F-017F-4376-8A53-7D473123D6C5
Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.
P2860
Q41386664-4F58DD0F-017F-4376-8A53-7D473123D6C5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41386664-4F58DD0F-017F-4376-8A53-7D473123D6C5
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
220e39875189e3bb9da07df3ee58a64cbbcefb4a
P2860
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.